Latest available resultsQuarter ended June 30, 202610-Q · August 5, 2026
Filed with the SECAMGEN INC
AMGNPharma & biotech
Next reportNovember 2, 2026after close · Analyst forecast 5.907 $/share
Revenue
$10.05B
▲ +9.5% vs prior year% YoY
Net income
$2.38B
▲ +65.9% vs prior year% YoY
EPS
4.37$
▲ +64.9% vs prior year% YoY
Net margin
23.6%
▲ +8.0 percentage points vs prior year pp YoY
Revenue▲ +9.5 %
Margins (% of revenue)GrossOperatingNet
Net income▲ +65.9 %
EPS▲ +64.9 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $10.05B | |
| Gross profit | $7.24B | 72.0 % |
| Operating income | $3.51B | 35.0 % |
| Net income | $2.38B | 23.6 % |
| R&D | — | never filed |
| EPS (diluted) | 4.37 $ | |
| Balance sheet | ||
| Assets | $95.64B | |
| Liabilities | $83.95B | |
| Equity | $11.69B | |
| Cash | $13.99B | |
| Capital | ||
| Shares outstanding | 540.63M | as of 2026-07-30 |
| Public float | — | |